Trials / Terminated
TerminatedNCT02619617
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
Detailed description
The purpose of this non-confirmatory study was to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study was a sequential design of SOM230 vs. Placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOM230 | The study evaluated SOM230 vs Placebo |
| DRUG | Placebo | The study evaluated SOM230 vs Placebo |
Timeline
- Start date
- 2016-10-31
- Primary completion
- 2018-09-25
- Completion
- 2018-09-25
- First posted
- 2015-12-02
- Last updated
- 2021-01-05
- Results posted
- 2020-01-13
Locations
4 sites across 3 countries: United States, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT02619617. Inclusion in this directory is not an endorsement.